Calton & Associates’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.6M Sell
6,542
-453
-6% -$106K 0.23% 89
2025
Q4
$1.45M Buy
6,995
+410
+6% +$81.1K 0.21% 95
2025
Q3
$1.22M Sell
6,585
-350
-5% -$60K 0.18% 102
2025
Q2
$1.06M Buy
6,935
+1,396
+25% +$215K 0.18% 99
2025
Q1
$919K Buy
5,539
+2,074
+60% +$325K 0.21% 96
2024
Q4
$501K Sell
3,465
-3,002
-46% -$465K 0.22% 102
2024
Q3
$1.05M Buy
6,467
+751
+13% +$120K 0.4% 57
2024
Q2
$835K Buy
5,716
+2,597
+83% +$386K 0.42% 63
2024
Q1
$493K Sell
3,119
-911
-23% -$145K 0.24% 95
2023
Q4
$632K Buy
4,030
+1,682
+72% +$258K 0.25% 93
2023
Q3
$366K Sell
2,348
-1,813
-44% -$299K 0.53% 50
2023
Q2
$689K Buy
4,161
+57
+1% +$9.2K 0.32% 77
2023
Q1
$636K Sell
4,104
-1,292
-24% -$209K 0.3% 83
2022
Q4
$953K Buy
5,396
+1,112
+26% +$192K 0.37% 70
2022
Q3
$699K Sell
4,284
-54
-1% -$9.14K 0.4% 63
2022
Q2
$770K Sell
4,338
-1,010
-19% -$180K 0.43% 60
2022
Q1
$947K Sell
5,348
-190
-3% -$32.3K 0.28% 93
2021
Q4
$947K Sell
5,538
-1,682
-23% -$275K 0.25% 106
2021
Q3
$1.17M Sell
7,220
-723
-9% -$123K 0.26% 102
2021
Q2
$1.31M Sell
7,943
-403
-5% -$66.7K 0.25% 85
2021
Q1
$1.37M Sell
8,346
-1,718
-17% -$278K 0.27% 74
2020
Q4
$1.58M Sell
10,064
-994
-9% -$147K 0.28% 68
2020
Q3
$1.65M Sell
11,058
-715
-6% -$106K 0.34% 61
2020
Q2
$1.66M Sell
11,773
-1,602
-12% -$233K 0.36% 59
2020
Q1
$1.75M Buy
13,375
+910
+7% +$129K 0.43% 51
2019
Q4
$1.82M Buy
12,465
+1,959
+19% +$266K 0.37% 58
2019
Q3
$1.36M Buy
10,506
+202
+2% +$26.6K 0.3% 64
2019
Q2
$1.44M Sell
10,304
-323
-3% -$44.7K 0.41% 47
2019
Q1
$1.49M Sell
10,627
-641
-6% -$85.9K 0.45% 44
2018
Q4
$1.45M Buy
11,268
+22
+0.2% +$3.07K 0.53% 36
2018
Q3
$1.55M Buy
11,246
+103
+0.9% +$13.7K 0.46% 35
2018
Q2
$1.46M Sell
11,143
-2,581
-19% -$322K 0.43% 38
2018
Q1
$1.76M Sell
13,724
-234
-2% -$31.6K 0.51% 35
2017
Q4
$1.98M Buy
+13,958
New +$1.94M 0.5% 31

Other funds holding JNJ

Calton & Associates's JNJ Position: Q1 2026 in Review

Calton & Associates reduced its Johnson & Johnson (JNJ) stake by 6.5% in Q1 2026, selling an estimated $106K and leaving 6,542 shares worth $1.6M. The position accounts for 0.23% of the portfolio, ranked #89.

Calton & Associates first reported a position in JNJ in Q4 2017 and has held it in 34 quarters since. The position peaked at $1.98M in Q4 2017. 4,616 funds tracked by Wall St. Rank hold JNJ as of Q1 2026.

  • Calton & Associates held 6,542 shares of Johnson & Johnson worth $1.6M as of Q1 2026.
  • Calton & Associates sold 453 Johnson & Johnson shares in Q1 2026, an estimated $106K.
  • Johnson & Johnson made up 0.23% of Calton & Associates's portfolio in Q1 2026, its #89 holding.
  • Calton & Associates first reported a position in Johnson & Johnson in Q4 2017 and has held it in 34 quarters since.
  • Calton & Associates's Johnson & Johnson position peaked at $1.98M in Q4 2017.
  • 4,616 funds tracked by Wall St. Rank held Johnson & Johnson as of Q1 2026.

Based on Calton & Associates's 13F filing for Q1 2026, filed 13 May 2026.